Ask Warren

Aprogen Biologics

003060 · KOSPI · ₩003060 · 에이프로젠바이오로직스

₩1,335▼ ₩45 (3.26%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩23B₩22B₩20B₩21B₩15B₩17B₩22B₩15B
Cost of sales₩33B₩26B₩27B₩23B₩25B₩24B₩31B₩15B
Gross profit−₩9.5B−₩4.7B−₩7.1B−₩2.3B−₩10B−₩7.4B−₩8.7B−₩89M
Operating income−₩17B−₩14B−₩16B−₩11B−₩18B−₩16B−₩16B−₩13B
Net income−₩5.1B−₩4.6B−₩144B₩42B−₩24B−₩43B−₩89B₩8B
Net income to shareholders−₩14B−₩3.9B−₩36B−₩24B−₩67B−₩43B−₩60B−₩15B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩548B₩577B₩587B₩603B₩600B₩638B₩591B₩631B
Current assets₩118B₩152B₩155B₩181B₩136B₩135B₩115B₩151B
Cash and equivalents₩22B₩24B₩24B₩22B₩26B₩36B₩12B₩26B
Total liabilities₩281B₩304B₩309B₩288B₩262B₩303B₩212B₩196B
Current liabilities₩207B₩227B₩229B₩211B₩192B₩237B₩148B₩132B
Borrowings₩190B₩210B₩208B₩192B₩161B₩176B₩136B₩107B
Total equity₩268B₩273B₩278B₩315B₩338B₩334B₩379B₩436B
Shareholders' equity₩194B₩204B₩208B₩244B₩268B₩334B₩378B₩436B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩6.8B−₩9.1B−₩8.9B−₩7.7B−₩11B−₩11B−₩8.6B−₩9.5B
Capital spending₩518M₩232M₩1.5B₩1.5B₩2.3B₩4.3B₩7.8B₩2.8B
Free cash flow−₩7.3B−₩9.3B−₩10B−₩9.2B−₩13B−₩15B−₩16B−₩12B
Dividends paid——₩0—————

Consolidated where available. Amounts in won.

Also known as: Aprogen Biologics / 에이프로젠바이오로직스 / 003060 / KRX:003060

Source: KRX statistical information